A protocol is presented for supine bicycle ergometry in healthy subjects, which aims for a target increase of heart rate (HR = 140 beats min-') after 4 min cycling under constant load. The required load is selected from a pre-study ergometry with stepwise increasing load. Repeated testing with this protocol was shown to yield highly reproducible ergometric HR-responses. Because of their high reliability, the ergometric endpoints and increments permit a highly sensitive comparison of ,13-adrenoceptor antagonism across dose and time within a given compound. The relationship between the changes of the ergometric rise of HR and the Pi-adrenoceptor occupancy (estimated from radioreceptor assay data) permits to evaluate the ergometric efficiency of different P-adrenoceptor antagonists across time and doses and to identify eventual differences that do not relate primarily to the extent of 13i-adrenoceptor antagonism itself.
Introduction
Bicycle ergometry is a routine method to evaluate Piadrenoceptor antagonism [1] . In order to achieve stable and highly sensitive end points and ergometric responses that are not affected by ancillary postural drug actions, a protocol was developed for supine bicycle ergometry in healthy subjects, the validation of which is reported here in conjunction with venous plasma radioreceptor assay data from various jadrenoceptor antagonists.
Methods

Study protocols
Drug-related changes of the responses to supine bicycle ergometry were assessed for propranolol (single doses of 40, 80 and 240 mg), metoprolol (600 mg), celiprolol (1000 and 1200 mg), talinolol (25, 50, 100 and 400 mg) and carvedilol (12.5, 25, 50 and 100 mg). All studies were conducted in healthy male subjects. Each time the same ergometric protocol was used. All evaluations relate to the kinetic maximum.
observations beyond Ergometric protocol
All ergometric studies were carried out in the supine position with the hips and knees flexed at an angle of approximately 900 and using one equipment for all tests in all subjects (Siemens Elema 380B Ergometry System®, Germany). Upon recruitment, the subjects were familiarised with the study environment and techniques. They performed a supine bicycle ergometry test with stepwise increasing watt-load (starting at 100 watt with increments of 25 watt every 1 min up to a maximum heart rate of 160 beats min-'). From this test, the watt-load corresponding with a target heart rate of 140 beats min-' was derived by linear interpolation. During the subsequent studies the same protocol was used for all tests: the watt-load (that yielded 140 beats min-1 upon recruitment) was maintained for 4 min, preceded and followed by 1 min 0-watt free peddling. Measurement of ergometric responses Heart rate (HR) derived from 1-lead ECG-strips recorded over 15 s and blood pressure (SBP/DBP, mm Hg, derived by stethoscope auscultation of Korotkoff I and IV sounds and using a mercury sphygmomanometer) were measured every minute. The time course of the attenuation of the ergometric rise of HR and SBP at the end of 4 min ergometry relative to placebo was then analysed as a measure of the rate and extent of fi-adrenoceptor blockade.
Environmental study conditions
All subjects were studied after an overnight fast of at least 10 h before the administration of the investigational treatments.
Assay of f3j-adrenoceptor occupancy On several occasions subsequent to the administration of the investigational f-adrenoceptor antagonists blood was sampled via an indwelling venous catheter, centrifuged immediately, the plasma separated and frozen for subsequent analysis. Plasma was subjected to a Pi-adreno-radioceptor assay (RRA) in order to assay the amount of drug related substrate capable of binding to Ii-adrenoceptors. [3H]-CGP 12177 (as the labelled ligand) and membranes prepared from rat salivary gland (as receptor source) were used [2] . The saturation isotherm of the radioligand was measured in order to determine the affinity for and the capacity of the ,3i-adrenoceptors. The concentrations of the unlabelled (,B-adrenoceptor blocking) substrate can then be expressed as multiples of its equilibrium dissociation constant (Ki) in plasma. From these concentrations the receptor occupancies (= 'effect') can be calculated assuming an hyperbolic Hill equation (sigmoidicity = 1) concentration-effect relationship [3] . For such assays, the limit of quantitation lies at about 0.20 to 0.25 times Ki which corresponds with occupancies of about 17-20%.
Data analysis
The ergometric responses were analysed in two formats: as ergometric end points after 4 min loaded cycling and as ergometric increments (arithmetic difference between end point and resting values before ergometry). The investigational ergometric effects were expressed as the difference between the ergometric responses for the active treatments minus those for placebo.
The observational variability of repeated exercise testing was analysed for 12 subjects who were investigated on 6 days at least 1 week apart, on each time with one ergometry prior to dosing and six ergometries subsequent to dosing (at 2, 4, 6, 9, 12 and 22 h after dosing). The pre-dosing ergometries were used to assess period effects and between-day variability. The pre-and post-dosing ergometries on the placebo study day were used to evaluate within-day variability, diurnal and/or prandial effects (meals were taken at 6 and 9 h after dosing). The variance estimates were used to calculate the inter-(bs) and intra-individual (ws) coefficients of within-(wd) and between-day (bd) reproducibility of HR and systolic blood pressure (SBP) at rest before the ergometry, at the end of 4 min cycling and for the corresponding ergometric increments. The coefficients of reproducibility represent the largest absolute difference reached with 95% confidence between two measurements of the same (ws) or different subjects (bs) either on the same day (wd) or on different study days (bd) [4, 5] . The corresponding residual variances were also used to calculate the minimal statistically significant difference (8) detectable in a sample of n = 12 with 95% confidence (a: 0.05) and 90% power (0:O.10).
Results
Average ergometric load
In 36 healthy male subjects (18 to 35 years of age) the average load derived by pre-study testing was 203 Watt (s.d.: 13, median: 201, 25% to 75% quantiles: 172 to 260 watt).
Reproducibility
The data are summarised in Table 1 . Within-subject reproducibilities were consistently better than those between subjects, within-day reproducibility tended to be better than between-day reproducibility and HR was better reproducible than SBP. Resting and ergometric HR were not affected by period effects whereas resting SBP (more than the ergometric increments) decreased progressively over time. The ergometric HR end points and ergometric increments were very reproducible. With n = 12, differences of the end points as small as about 5 beats min-' (grand mean of 145 beats min-') would have reached statistical significance (a: 0.05, P:10), which allows precise and sensitive contrasts between doses and time points [6] .
Relationship between ergometric effects and f31-adrenoceptor occupancies
The relationships between the ergometric effects and the respective ,1-adrenoceptor occupancies at various time points after the administration of several Padrenoceptor antagonists (investigated in separate studies that were conducted under similar methodological conditions) are presented in Figure 1 .
Ergometric responses of venous plasma catecholamines
The ergometry caused a rise of venous plasma noradrenaline (+493, s.d. 291 ng ml-', n = 12) and adrenaline (+118, s.d. 90 ng ml-, n = 12) as measured by specific h.p.l.c. assay [7] . Table 1 Reproducibility of ergometric heart rate (HR, beats min-') and systolic blood pressure (SBP, mm Hg) for observations at rest (baseline), after 4 min constant load ergometry (end points) and for the difference between end point and resting baseline (increments). The between-study day evaluation is based on the pre-dosing ergometry on 6 consecutive study days. The withinstudy day evaluation is based upon repeated ergometries before and at 2, 4, 6, 9, 12 and 22 h after administration of placebo. The means (n = 12) at the various time points (MX..) are tabulated. The F-test evaluates differences between these means (S: significant, NS: not significant, a: 0.05). 8 is the smallest significant difference between these means that could be detected with 95% confidence and 90% power for a sample size of n = 12. REP is the reproducibility coefficient within same subject (wsREP) or between different subjects (bsREP).
Between-study day reproducibility (pretreatment ergometries) Vari MX (PI) MX (P2) MX (P3) MX 
Discussion
The ergometric effects at various time points (up to 24 h) after the administration of 40, 80 and 240 mg propranolol correlated in a smoothly linear fashion with the I01-adrenoceptor occupancies derived by RRA (see Figure 1 ; low occupancies relate to time points late after dosing). According to these graphs, maximum ,-adrenoceptor occupancy affects only about half of the total ergometric HR-increment. But, [8] . J-adrenoceptor subtype 'selectivity' itself is not an explanation of this feature as the 'bonus' is monotonously maintained for both drugs even at doses and/or concentrations where 01-adrenoceptor selectivity is lost. The analysis furthermore allows differentiation of celiprolol's somewhat peculiar ergometric effects: high doses of celiprolol (1000 and 1200 mg), which have both ,13-adrenoceptor antagonistic and 12-adrenoceptor agonistic properties [9] , cause a relatively flat reduction of the ergometric end-points whereas the reduction of the ergometric increments is relatively similar to that of propranolol and metoprolol. This might indicate that the celiprolol-related increase of resting HR observed at these doses is maintained throughout the increased sympathetic tone of exercise and results from a mechanism which is merely (arithmetically) additive to the 3i-adrenoceptor blockade. Alternatively, this might reflect eventual partial 3i-adrenoceptor agonistic properties [10] which at high doses begins to offset dose-related ,1-adrenoceptor blockade.
In conclusion these findings validate the chosen protocol for supine bicycle ergometry in the evaluation of J1-adrenoceptor antagonists as it yields sensitive, well-reproducible and consistent responses. The analysis of such ergometric data in conjunction with 3-adrenoceptor occupancy data derived by radioreceptor assay adds relevance to the ergometric observations as it permits assessment of differences across doses, time and compounds independent of distinctions in j31-adrenoceptor occupancy.
